Sunmax Biotechnology Co., Ltd. (TPEX:4728)

Market Cap	25.82B
Revenue (ttm)	1.82B
Net Income (ttm)	679.41M
Shares Out	54.46M
EPS (ttm)	12.46
PE Ratio	38.04
Forward PE	n/a
Dividend	11.60 (2.45%)
Ex-Dividend Date	Jul 17, 2024

Volume	84,273
Average Volume	90,889
Open	464.50
Previous Close	473.50
Day's Range	464.50 - 485.00
52-Week Range	228.50 - 485.00
Beta	-0.01
RSI	77.61
Earnings Date	Mar 27, 2025

About Sunmax Biotechnology

Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets collagen-based medical devices in Taiwan and Mainland China. The company offers dermal fillers, including Sunmax FACIALGAIN collagen implant with lidocaine, Sunmax collagen implant I-Plus, Sumax collagen implant I, Sunmax FACIALGAIN collagen implant 1-Plus with lidocaine for the correction of facial defects, such as the fill up of wrinkles; and Porcogen, a sterile purified collagen solution for medical device, tissue engineering, and research purposes. It ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4728

Financial Performance

In 2024, Sunmax Biotechnology's revenue was 1.82 billion, an increase of 7.64% compared to the previous year's 1.69 billion. Earnings were 679.41 million, an increase of 8.58%.